Market Access Growth Genesis recently launched US Market Access data analytics, signaling a deliberate expansion in payer-focused offerings. For business development, target life-science sponsors needing payer and HTA support, evidence generation for reimbursement, and access strategy. Propose bundled services combining RWE, HEOR, and market access to accelerate dossiers and payer engagement.

Pricing Leadership Appointment of Tim Wright as Executive Vice President, Access and Pricing in July 2025 highlights a strategic emphasis on pricing and market access. For BD, engage pricing-focused roles at pharma/biotech clients to offer value-based pricing models, payer negotiation-ready HEOR packages, and price realization analytics that improve market uptake.

RWE and HEOR Core Genesis provides real-world evidence, HEOR, and stakeholder insights (RPR) through a data-agnostic engagement model to help partners anticipate payer, regulator, and stakeholder needs. For sales teams, position end-to-end RWE/HEOR programs for HTA submissions, post-launch evidence plans, and global evidence generation, emphasizing flexibility in data sources.

Global Expansion The firm delivers US and global real-world evidence and has activity in Europe; recent news includes collaboration with Evidence Base to refresh payer-focused content and events that underscore international reach. For BD, target sponsors expanding to US/Europe, propose cross-border evidence programs and joint data analytics to support global market access plans.

Strategic Partnerships A history of strategic partnerships and leadership changes, including Rallyday investment exit and ongoing collaborations, signals a collaborative go-to-market approach and growing revenue footprint. For BD, explore alliances with CROs, data providers, and policy-focused consultancies to co-sell integrated RWE/HEOR and market access solutions; propose joint offerings that leverage Genesis' stakeholder insights (RPR) and data-agnostic approach.